BioSpace News Archive

Amylyx Adds Data from CENTAUR to the Anonymized PRO-ACT Database, the Largest ALS Clinical Trial Dataset Ever Created

Cellworks Group, Inc. today announced that results from patient stratification studies will be featured in four poster presentations at the IASLC 2021 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer and held virtually September 8-14, 2021.

Cannabics Pharmaceuticals Inc. announced today that Dr. Ilya Reznik (MD), a renowned Neuropsychiatrist, has joined the company as Head of Psychedelic Inspired Medicine.

OSE Immunotherapeutics SA announced that promising data from dose escalation Phase 1 of selective SIRPα inhibitor BI 765063 in patients with advanced solid tumors will be presented at the 2021 European Society for Medical Oncology Virtual Conference to be held on September 16 – 21, 2021.

Harbour BioMed announced positive results from its phase I dose escalation clinical trial of HBM4003 in solid tumors in Australia.

Medivir AB announced that the Abstract entitled “Phase 1 study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma, intrahepatic cholangiocarcinoma or liver metastases " has been released on the European Society for Medical Oncology website.

Providence Therapeutics announced additional results from its Phase 1 study, PRO-CL-001, of PTX-COVID19-B.

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, announced that the U.S. Food and Drug Administration has approved the initiation of a Phase 1 clinical trial of HMBD-002, Hummingbird’s anti-VISTA neutralizing antibody.

Immunovia AB, a diagnostic company that develops and sells highly accurate blood tests for the early detection of cancer, announced that Immunovia has strengthened its patent protection for pancreatic cancer biomarkers by obtaining a global license from the South Korean company JW BioScience’s IP portfolio.

Relay Therapeutics, Inc. announced that initial clinical data for RLY-4008 and preclinical data for RLY-2608 have been selected for a plenary oral and poster presentation, respectively, at the upcoming virtual AACR-NCI-EORTC Molecular Targets Conference, being held October 7-10, 2021.